Powerful Dual Mass Spectrometry Imaging Workflows for MALDI-based
Molecular Imaging Yield Spatial Drug and Metabolite Distributions in
Tissue, and Assist Biomarker Discovery and Validation
ORLANDO, Fla.--(BUSINESS WIRE)--
At the 10th International Society for the Study of
Xenobiotics (ISSX) meeting, Bruker (NASDAQ: BRKR) today announced the
novel Molecular Drug Imager™ solution for
pre-clinical drug and metabolite imaging.
MALDI-based tissue imaging for pharmaceutical development has provided
researchers with a powerful technique for localizing small molecule
drugs and their metabolites, or lipids, within tissue structures,
providing key insights into physiological function that were unavailable
with previous technologies. With its powerful software and workflow
flexibility, the new Molecular Drug Imager solution is
poised to take small molecule mass spectrometry imaging (MSI) to the
next level by empowering fast, accurate, and thorough evaluation of drug
candidates and their metabolites in model tissues and beyond.
For more than a decade, Bruker has provided industry-leading advances in
hardware and methods for MALDI-based mass spectrometry imaging. The
recently introduced rapifleX™ MALDI-TOF system has set new
standards for speed and pixel fidelity for protein imaging and molecular
histology research, while the solariX XR™ FTMS system
successfully merged MALDI small molecule imaging with Isotopic Fine
Structure (IFS) analysis for undisputable molecular formula specificity.
The Molecular Drug Imager leverages the unparalleled power
of solariX-based small molecule imaging to provide a comprehensive
analysis-to-answer imaging workflow solution to enable pharmaceutical
investigators at all levels, from biomarker discovery and validation to
drug development studies. Many of the top-25 pharma companies are
already using earlier versions of this MSI technology in their
pre-clinical efforts to complement or replace expensive workflows, such
as Quantitative Whole-Body Autoradiography (QWBA), and to migrate
certain animal based pre-clinical models to tissue proxies.
About the Molecular Drug Imager
Providing traditional MALDI imaging analysis functions such as combining
optical and molecular images, the Molecular Drug Imager in
its first workflow facilitates localizing multi-generational metabolic
products of drug candidates by in silico metabolism followed by
automated image generation of predicted metabolites in analyzed tissues.
This results in a significant time savings through automation of this
critical workflow, which is becoming commonplace in advanced
laboratories worldwide.
The second advanced workflow provides a rapid discovery tool based on
comprehensive statistical treatment of imaging datasets. Powered by the
SCiLS lab software suite, powerful next-generation statistical
algorithms such as PLSA and univariate and multivariate modalities can
rapidly analyze imaging regions to identify unknown metabolites and
biomarkers through spatial co-localization.
The Molecular Drug Imager solution is also being featured
simultaneously at the Society for Toxicological Pathology Meeting in
Minneapolis, Minnesota on October 17-21.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance instruments and
high-value analytical solutions enable scientists to explore life and
materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, in microscopy, Nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151021006418/en/
Source: Bruker Corporation